xCT Antibody - BSA Free

xCT, also called SLC7A11, is the light chain component of the cysteine/glutamate amino acid exchange transporter system Xc (1,2). System Xc is composed of two subunits, the light chain (xCT) and the heavy chain (CD98hc, SLC3A2) and functions by cellular uptake of cysteine in exchange for glutamate in a 1:1 ratio (1,2). The human xCT gene is located on chromosome 4q28.3 and is synthesized as a 12-pass transmembrane protein with both the N- and C-terminals located intracellularly (2, 3). xCT is a 501 amino acids (aa) protein with a theoretical molecular weight of 55.4 kDa (3, 4). xCT expression serves many functional purposes in cells including redox balance, ferroptosis, and chemotherapy or cancer drug resistance (1-3, 5-7). Import of cysteine by xCT plays a role in promoting oxidative stress response as cysteine is a precursor for glutathione synthesis (2, 3, 5-7). Glutathione is a cofactor for ROS-detoxifying enzymes, including glutathione peroxidase (GPX), which help defend from cellular ROS-induced damage (2, 3, 5-7). In addition to its antioxidant role, xCT also utilizes glutathione and GPX to inhibit ferroptosis, which is iron-dependent, non-apoptotic cell-death that occurs with overproduction of lipid hydroperoxides (1-3, 5-7). As cancer cells often experience high oxidative stress, it is understandable that xCT is overexpressed in a variety of cancer types, such as acute myeloid leukemia and breast cancer, and affects cancer growth, invasion, metastasis, and prognosis (1-3, 5-7). xCT expression has also been shown to play a role in glutathione-mediated drug resistance during cancer treatment (1,5,7). However, studies have shown that xCT knockdown results in increased tumor cell death, highlighting its suitability as a druggable target (1,5,7). Specifically, the xCT inhibitors Sulfasalazine, an approved anti-inflammatory drug, and Erastin, a small molecule inhibitor, are potential therapeutic modalities for treating a variety of cancers when used in combination with radiotherapy or immunotherapy (1-3, 5-7).

References

1. Liu, J., Xia, X., & Huang, P. (2020). xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling. Molecular therapy : the journal of the American Society of Gene Therapy. https://doi.org/10.1016/j.ymthe.2020.08.021

2. Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018). Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer communications. https://doi.org/10.1186/s40880-018-0288-x

3. Lin, W., Wang, C., Liu, G., Bi, C., Wang, X., Zhou, Q., & Jin, H. (2020). SLC7A11/xCT in cancer: biological functions and therapeutic implications. American journal of cancer research.

4. xCT: Uniprot (Q9UPY5)

5. Koppula, P., Zhuang, L., & Gan, B. (2020). Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein & cell. https://doi.org/10.1007/s13238-020-00789-5

6. Liu, L., Liu, R., Liu, Y., Li, G., Chen, Q., Liu, X., & Ma, S. (2020). Cystine-glutamate antiporter xCT as a therapeutic target for cancer. Cell biochemistry and function. https://doi.org/10.1002/cbf.3581

7. Cui, Q., Wang, J. Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Jr, Yang, D. H., & Chen, Z. S. (2018). Modulating ROS to overcome multidrug resistance in cancer. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. https://doi.org/10.1016/j.drup.2018.11.001

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Human, Mouse, Rat.

We have publications tested in 4 applications: Block/Neutralize, IHC-Fr, IHC-P, WB.

Showing Publications 1 - 10 of 10.

Publications using NB300-317	Applications	Species
Wang J, Wang Y, Liu Y et al. Ferroptosis, a new target for treatment of renal injury and fibrosis in a 5/6 nephrectomy-induced CKD rat model Cell death discovery 2022-03-22 [PMID: 35318301] (IHC-P, Rat)	IHC-P	Rat
Zhang HF, Hughes CS, Li W et al. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma Cancer Discovery 2021-11-01 [PMID: 34021002]
Martinez R 3rd, Huang W, Samadani R et al. Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress Journal of Pharmacology and Experimental Therapeutics 2021-01-01 [PMID: 33109619] (Block/Neutralize)	Block/Neutralize
Long Y, Tao H, Karachi A et al. Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma Cancer Res. 2019-11-13 [PMID: 31723000] (IHC-Fr, Mouse)	IHC-Fr	Mouse
Huang M, Lin Y, Chang C et al. RGS4 deficit in prefrontal cortex contributes to the behaviors related to schizophrenia via system xc--mediated glutamatergic dysfunction in mice. Theranostics 2018-09-13 [PMID: 30279737] (WB, Mouse)	WB	Mouse
Chew SH, Okazaki Y, Akatsuka S et al. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma. Free Radic. Biol. Med. 2017-02-06 [PMID: 28185919]
Linher-Melville K, Haftchenary S, Gunning P et al. Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells. Mol. Cell. Biochem. 2015-04-21 [PMID: 25896132] (WB, Human)	WB	Human
Pampliega O, Domercq M, Soria FN et al. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation. 2011-06-01 [PMID: 21639880] (IHC-Fr, Rat, Human)	IHC-Fr	Rat, Human
Liu, R et al. Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol;72(6):1637-46. 2007-12-01 [PMID: 17875604] (WB, Human)	WB	Human
Davidson-Hunt A Supplemental glutamine to restore glutathione homeostasis in the aging mouse liver Thesis 2022-01-01 (WB, Mouse) Details: Dilution used in WB 1:500	WB	Mouse

Images	Ratings	Applications	Species	Date	Details
Enlarge	4 reviewed by: Diane Brooks	Simple Western	Human	01/18/2018	View Summary Application Simple Western Sample Tested Human Brain Tissue,human glioblastoma Species Human Lot D1 Comments Comments Membrane lysates were extracted using ThermoFisher Mem-PER Plus Membrane Protein Extraction Kit Cat# 89842. Samples were reduced following Simple Western kit instructions in 40mM DTT for 5 minutes at 95oC and separated using the 12-230kDa separation kit. Primary antibody followed by HRP-conjugated Anti-Rabbit IgG secondary antibody (Protein Simple Cat # 042-206).

Array NB300-317

• xCT Antibodies
• xCT Proteins